Teck’s Q2 2018 Financial Results and Investors’

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
30
Teck’s Q2 2018 Financial Results and Investors’ Conference Call July 26, 2018

VANCOUVER, British Columbia, June 26, 2018 (GLOBE NEWSWIRE) -- Teck Resources Limited (TSX:TECK.A) (TSX:TECK.B) (NYSE: TECK ) (“Teck”) will release its second quarter 2018 earnings results on Thursday, July 26, 2018 before market open.

The company will hold an investor conference call to discuss the second quarter 2018 earnings results at 11:00 a.m. Eastern time / 8:00 a.m. Pacific time on Thursday, July 26, 2018. The conference call dial-in is 416.340.2216 or toll free 866.225.0198, no pass code required. Media are invited to attend on a listen-only basis.

A live audio webcast of the conference call, together with supporting presentation slides, will be available on Teck's website at www.teck.com .

The recording of the live audio webcast will be available from 10:00 a.m. Pacific time July 26, 2018 on Teck’s website at www.teck.com .

About Teck Teck is a diversified resource company committed to responsible mining and mineral development with major business units focused on copper, steelmaking coal, zinc and energy. Headquartered in Vancouver, Canada, its shares are listed on the Toronto Stock Exchange under the symbols TECK.A and TECK.B and the New York Stock Exchange under the symbol TECK.  Learn more about Teck at  www.teck.com  or follow  @TeckResources .

Investor Contact: Ellen Lai Coordinator, Investor Relations 604.699.4257 ellen.lai@teck.com

Media Contact: Chris Stannell Senior Communications Specialist 604.699.4368 chris.stannell@teck.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

FDA Greenlights Kisqali®: A Major Step for Breast Cancer Care

Updated Category News Views 203

Kisqali® Receives FDA Approval for Early Breast Cancer Treatment Novartis has some exciting news for oncology: the US Food and Drug Administration (FDA) has officially approved Kisqali® (ribociclib) as a treatment for patients diagnosed with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) stage II and III early breast cancer...

Continue Reading
Ålandsbanken Abp Launches SEK 350M Additional Tier 1 Notes Series

Updated Category News Views 162

Ålandsbanken Abp Issues SEK 350,000,000 Additional Tier 1 Notes Ålandsbanken Abp, a prominent player in the banking industry, recently made waves in the financial market by issuing Additional Tier 1 floating rate notes amounting to SEK 350,000,000. The issuance marks a significant step in Ålandsbanken's strategic move to strengthen its capital position and enhance its...

Continue Reading
Harbour BioMed's 2025 Achievements and Future Prospects

Updated Category News Views 249

Harbour BioMed Achieves Significant Milestones in Interim Results Harbour BioMed (HKEX: 02142) is a prominent biopharmaceutical company focused on developing innovative antibody therapeutics, particularly in the fields of immunology and oncology. The company shared its impressive interim results for the first half of the year, showcasing remarkable growth and strategic...

Continue Reading
Innovative Investment Fuels Okika Devices' Future Growth Strategy

Updated Category News Views 187

Strategic Investment Boosts Okika Devices Advancement Colorado ONE Fund, which is part of the ONE Funds initiative, has made a major investment in Okika Devices, a company recognized for its innovation in Field Programmable Analog Array (FPAA) technology. This investment aligns with Colorado ONE Fund's mission to support technologies that advance the local innovation...

Continue Reading
Investors Take Note: Legal Options for Shareholders Explored

Updated Category News Views 61

Exploring Legal Options for Investors in Major Companies In recent developments, Halper Sadeh LLC, a reputable law firm focusing on investor rights, is carefully examining three significant companies for potential violations of federal securities laws. This investigation centers around the actions and decisions made by these firms, which may affect shareholders' rights...

Continue Reading